Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up - What's Next?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s share price gapped up prior to trading on Friday . The stock had previously closed at $12.35, but opened at $12.93. Stoke Therapeutics shares last traded at $12.75, with a volume of 96,492 shares changing hands.

Analyst Ratings Changes

STOK has been the topic of a number of recent research reports. HC Wainwright dropped their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a research report on Friday. They set a "buy" rating and a $30.00 price target on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of "Buy" and an average target price of $25.80.

Stoke Therapeutics Stock Up 7.0%

The business's 50-day moving average is $10.97 and its two-hundred day moving average is $9.63. The company has a market capitalization of $721.81 million, a P/E ratio of 16.73 and a beta of 1.14.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of Stoke Therapeutics stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the sale, the insider owned 25,782 shares of the company's stock, valued at approximately $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 9.50% of the stock is owned by insiders.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC raised its position in Stoke Therapeutics by 1,842.0% in the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after acquiring an additional 5,084 shares during the period. KLP Kapitalforvaltning AS bought a new stake in Stoke Therapeutics in the fourth quarter worth about $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics in the fourth quarter worth about $113,000. AlphaQuest LLC bought a new stake in Stoke Therapeutics in the first quarter worth about $72,000. Finally, US Bancorp DE raised its position in Stoke Therapeutics by 9,743.9% in the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after acquiring an additional 11,108 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.